Betaliq, Inc.

Betaliq, Inc., is a clinical stage pharmaceutical company with a therapeutic focus on Glaucoma, founded in 2018 through a collaboration with Novaliq GmbH.

Betaliq is developing a global portfolio of topical glaucoma treatments based on the unique EyeSol® topical delivery system developed by Novaliq, GMBH. Our unique water-free eye drop technology offers increased residency time and enhanced absorption to provide the needed efficacy, while using less total drug. EyeSol® based eye drops don’t require chemical preservatives, like benzalkonium chloride, that can cause damage to the ocular surface, while being dispensed in a traditional eye drop bottle.